Eli Lilly weight loss drug beats Ozempic in head-to-head study
Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic ...
Seeking Alpha21m
Eli Lilly Targets IBD, Takes Calculated Gamble With $3.2bn Morphic Deal
Eli Lilly and Company is set to acquire Morphic Holding for $3.2bn. Morphic is focused on autoimmune disease drugs.
GEN44m
Lilly to Acquire Morphic for $3.2B, Adding Phase II IBD Programs
Eli Lilly has agreed to acquire Morphic Therapeutic for $3.2 billion, in a deal designed to expand the buyer’s chronic ...
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
Chicago, IL – July 8, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity ...
SchaeffersResearch.com2h
More Records Highs for Eli Lilly Stock After Buyout
Eli Lilly (LLY) and Morphic (MORF) are both higher today, following news that the former will acquire the latter ...
Eli Lilly acuerda comprar biotecnológica estadounidense Morphic por US$3.200 millones
Eli Lilly & Co. acordó comprar Morphic Holding Inc., fabricante estadounidense de fármacos para el intestino, por alrededor ...
FierceBiotech4h
Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster
Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda ...
Lilly Agrees to Buy Waltham-based biotech Morphic in $3.2 Billion Deal
(Bloomberg) — Eli Lilly agreed to buy Waltham-based gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some ...